Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy

Cindy M. Pabon; Piyush Kumar-Sharma; Benjamin O. Spieler; Daniel Tuerff; Jashodeep Datta; Peter J. Hosein

doi:10.1016/j.soc.2025.10.008

Back

Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy

Journal article

Peer reviewed

Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy

Cindy M. Pabon, Piyush Kumar-Sharma, Benjamin O. Spieler, Daniel Tuerff, Jashodeep Datta and Peter J. Hosein

Surgical oncology clinics of North America, Vol.35(2)

2026-01

DOI: https://doi.org/10.1016/j.soc.2025.10.008

PMID: 41903993

Appears in Miller School of Medicine - Latest Publications

Abstract

EBV

HRD

Immune checkpoint inhibitors

POLE

Tumor microenvironment

Efforts to expand immunotherapy benefit in gastrointestinal cancers focus on identifying subsets that may be more responsive to checkpoint blockade, developing combination strategies to overcome immunotherapy resistance, and leveraging the tumor microenvironment to enhance immune responsiveness in traditionally non-immunogenic malignancies.

Metrics

7 Record Views

Details

Title: Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy
Creators: Cindy M. Pabon - University of Miami
Piyush Kumar-Sharma - Division of Surgical Oncology, Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA
Benjamin O. Spieler - University of Miami
Daniel Tuerff - Division of Medical Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
Jashodeep Datta - University of Miami
Peter J. Hosein - University of Miami
Publication Details: Surgical oncology clinics of North America, Vol.35(2)
Publisher: Elsevier Inc; PHILADELPHIA
Number of pages: 19
Grant note: Sylvester K12 programNational Cancer Institute, United States (NCI) of the National Institutes of Health, United States (NIH): K12CA226330 NIH R01: R01CA294824-01, NIH-NCI 2K12CA226330-06, NCT06040099 V Foundation for Cancer Research, United StatesHelene & Bernard Herskowitz Fund for Pancreatic Cancer ResearchEsther Finkelstein Family Fund for Pancreatic Cancer ResearchLuis Rios Family Fund for Pancreatic Cancer ResearchGardner Fund for Pancreatic Cancer ResearchJo-Ann Forster familyNCI/NIH: P30CA240139
C.M. Pabon: Funding from the Sylvester K12 program, supported by the National Cancer Institute, United States (NCI) of the National Institutes of Health, United States (NIH) under Award Number K12CA226330. B.O. Spieler: Funding from: NIH R01 (R01CA294824-01) , Sylvester K12 program (NIH-NCI 2K12CA226330-06) . Consul-tant: Member of the executive steering committee for the AstraZeneca-sponsored Emerald Y90 trial (NCT06040099) , for which no payment is received. P.J. Hosein: Consultant for: Fibrogen, RevMed, and BetaGlue. Funding from: The V Foundation for Cancer Research, United States, The Helene & Bernard Herskowitz Fund for Pancreatic Cancer Research, The Esther Finkelstein Family Fund for Pancreatic Cancer Research, The Luis Rios Family Fund for Pancreatic Cancer Research, the Gardner Fund for Pancreatic Cancer Research, the Jo-Ann Forster family, and the Resnick Family. Research reported in this publication was also supported by the NCI/NIH Award P30CA240139.
Academic Unit: Miller School of Medicine; UMMG Department of Surgery; UMMG Dept of Medicine - Hematology/Oncology; UMMG Dept of Surgery - Div of Surgical Oncology
Language: English
Resource Type: Journal article
PMID: 41903993
Record Identifier: 991032963676902976